Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Among authors: mcilroy g. Lancet Rheumatol. 2024 Jun;6(6):e339-e351. doi: 10.1016/S2665-9913(24)00065-1. Epub 2024 May 8. Lancet Rheumatol. 2024. PMID: 38734019 Free article. Clinical Trial.
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, Otter A, McSkeane T, Rolfe H, Faustini S, Wall N, Hillmen P, Pratt G, Paneesha S, Zuo J, Richter A, Moss P. Parry H, et al. Among authors: mcilroy g. Blood Cancer J. 2021 Jul 30;11(7):136. doi: 10.1038/s41408-021-00528-x. Blood Cancer J. 2021. PMID: 34330895 Free PMC article. Clinical Trial.
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.
Parry H, McIlroy G, Bruton R, Damery S, Tyson G, Logan N, Davis C, Willett B, Zuo J, Ali M, Kaur M, Stephens C, Brant D, Otter A, McSkeane T, Rolfe H, Faustini S, Richter A, Lee S, Wandroo F, Shafeek S, Pratt G, Paneesha S, Moss P. Parry H, et al. Among authors: mcilroy g. J Hematol Oncol. 2022 Jan 9;15(1):3. doi: 10.1186/s13045-021-01219-7. J Hematol Oncol. 2022. PMID: 35000597 Free PMC article.
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.
McIlroy G, Lax S, Gaskell C, Jackson A, Rhodes M, Seale T, Fox S, Hopkins L, Okosun J, Barrington SF, Ringshausen I, Ramsay AG, Calaminici M, Linton K, Bishton M. McIlroy G, et al. BMC Cancer. 2024 Mar 25;24(1):370. doi: 10.1186/s12885-024-12112-0. BMC Cancer. 2024. PMID: 38528445 Free PMC article.
COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia.
Parry H, Bruton R, Roberts T, McIlroy G, Damery S, Sylla P, Dowell AC, Tut G, Lancaster T, Bone D, Willett B, Logan N, Scott S, Hulme S, Jadir A, Amin U, Nicol S, Stephens C, Faustini S, Al-Taei S, Richter A, Blakeway D, Verma K, Margielewska-Davies S, Pearce H, Pratt G, Zuo J, Paneesha S, Moss P. Parry H, et al. Among authors: mcilroy g. Cancer Cell. 2022 Jun 13;40(6):584-586. doi: 10.1016/j.ccell.2022.05.001. Epub 2022 May 6. Cancer Cell. 2022. PMID: 35588735 Free PMC article. No abstract available.
Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
Kinsella FAM, Inman CF, Gudger A, Chan YT, Murray DJ, Zuo J, McIlroy G, Nagra S, Nunnick J, Holder K, Wall K, Griffiths M, Craddock C, Nikolousis E, Moss P, Malladi R. Kinsella FAM, et al. Among authors: mcilroy g. Leuk Res. 2019 Aug;83:106173. doi: 10.1016/j.leukres.2019.106173. Epub 2019 Jun 18. Leuk Res. 2019. PMID: 31276965
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, Brock K, De Lavallade H, Craddock C, Clark RE, Smith ML, Fletcher R, Bishop R, Milojkovic D, Yap C. Copland M, et al. Among authors: mcilroy g. Lancet Haematol. 2022 Feb;9(2):e121-e132. doi: 10.1016/S2352-3026(21)00370-7. Epub 2021 Dec 11. Lancet Haematol. 2022. PMID: 34906334 Free article. Clinical Trial.
61 results